celecoxib has been researched along with Infections, Helicobacter in 19 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To test whether the chronic users of celecoxib, a selective cyclo-oxygenase-2 inhibitor, had less Helicobacter pylori-related intestinal metaplasia or if such users' intestinal metaplasia could be prone to disappear after H." | 7.74 | Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. ( Cheng, HC; Hung, KH; Liou, MF; Sheu, BS; Wu, JJ; Yang, HB, 2007) |
| "Celecoxib was as effective as lansoprazole co-therapy in the prevention of recurrences of ulcer complications in subjects with a history of NSAID-related complicated peptic ulcers." | 5.11 | Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. ( Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM, 2005) |
| "To see whether celecoxib prevents gastric cancer occurrence by disrupting the progression of chronic gastritis into gastric carcinoma through its inhibition of the migration of CD133-positive cells, one of the surface markers of bone marrow-derived cells, in Helicobacter pylori-infected gerbils." | 3.76 | Celecoxib inhibits CD133-positive cell migration via reduction of CCR2 in Helicobacter pylori-infected Mongolian gerbils. ( Futagami, S; Gudis, K; Hamamoto, T; Horie, A; Kawagoe, T; Nagoya, H; Sakamoto, C; Shimpuku, M; Shindo, T, 2010) |
| "To test whether the chronic users of celecoxib, a selective cyclo-oxygenase-2 inhibitor, had less Helicobacter pylori-related intestinal metaplasia or if such users' intestinal metaplasia could be prone to disappear after H." | 3.74 | Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. ( Cheng, HC; Hung, KH; Liou, MF; Sheu, BS; Wu, JJ; Yang, HB, 2007) |
| " Rofecoxib taken at supra-therapeutic dosage was recognised to increase the incidence of myocardial infarction." | 3.72 | [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. ( Lamarque, D, 2004) |
| "Celecoxib (COX-2 inhibitor) inhibits gastric cancer cell proliferation, but with low treatment efficacy, limiting its applications." | 1.42 | Anti-LeY antibody enhances therapeutic efficacy of celecoxib against gastric cancer by downregulation of MAPKs/COX-2 signaling pathway: correlation with clinical study. ( Aziz, F; Wang, X; Yan, Q; Yang, X, 2015) |
| "pylori-induced gastric cancer cell motility and invasion." | 1.39 | Celecoxib inhibits Helicobacter pylori-induced invasion of gastric cancer cells through an adenine nucleotide translocator-dependent mechanism. ( Fan, L; Fang, D; Guo, GJ; Lan, C; Wan, S; Wang, J; Wang, R; Yang, L; Yang, S; Zhang, Y, 2013) |
| "Celecoxib treatment decreased the incidence of EA in rats undergoing EJA with H." | 1.37 | Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux. ( Gao, PP; Li, J; Liu, FX; Wang, J; Wang, WH, 2011) |
| "Celecoxib treatment significantly reduced MPO activity, TBARS levels and the incidence of gastric cancer." | 1.35 | Celecoxib inhibits apurinic/apyrimidinic endonuclease-1 expression and prevents gastric cancer in Helicobacter pylori-infected mongolian gerbils. ( Crowe, SE; Futagami, S; Gudis, K; Hamamoto, T; Horie, A; Kawagoe, T; Kusunoki, M; Miyake, K; Sakamoto, C; Shindo, T; Suzuki, K; Tsukui, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lan, C | 1 |
| Yang, L | 1 |
| Fan, L | 1 |
| Zhang, Y | 3 |
| Wang, J | 2 |
| Guo, GJ | 1 |
| Wan, S | 1 |
| Yang, S | 1 |
| Wang, R | 1 |
| Fang, D | 1 |
| Nakamura, M | 1 |
| Takahashi, T | 1 |
| Matsui, H | 1 |
| Takahashi, S | 1 |
| Murayama, SY | 1 |
| Suzuki, H | 1 |
| Tsuchimoto, K | 1 |
| Aziz, F | 1 |
| Yang, X | 1 |
| Wang, X | 1 |
| Yan, Q | 1 |
| Pan, KF | 3 |
| Zhang, L | 3 |
| Ma, JL | 3 |
| Zhou, T | 1 |
| Li, JY | 3 |
| Shen, L | 2 |
| You, WC | 3 |
| Zeng, HM | 1 |
| Nie, XR | 1 |
| Futagami, S | 3 |
| Kawagoe, T | 2 |
| Horie, A | 2 |
| Shindo, T | 3 |
| Hamamoto, T | 3 |
| Suzuki, K | 2 |
| Kusunoki, M | 2 |
| Miyake, K | 2 |
| Gudis, K | 3 |
| Tsukui, T | 2 |
| Crowe, SE | 1 |
| Sakamoto, C | 3 |
| Zhang, LJ | 1 |
| Wang, SY | 1 |
| Huo, XH | 1 |
| Zhu, ZL | 1 |
| Chu, JK | 1 |
| Ma, JC | 1 |
| Cui, DS | 1 |
| Gu, P | 1 |
| Zhao, ZR | 1 |
| Wang, MW | 1 |
| Yu, J | 1 |
| Hung, KH | 2 |
| Yang, HB | 3 |
| Cheng, HC | 3 |
| Wu, JJ | 2 |
| Sheu, BS | 3 |
| Shimpuku, M | 1 |
| Nagoya, H | 1 |
| Oshima, H | 1 |
| Hioki, K | 1 |
| Popivanova, BK | 1 |
| Oguma, K | 1 |
| Van Rooijen, N | 1 |
| Ishikawa, TO | 1 |
| Oshima, M | 1 |
| Liu, FX | 1 |
| Wang, WH | 1 |
| Li, J | 2 |
| Gao, PP | 1 |
| Wong, BC | 2 |
| Liu, WD | 1 |
| Feng, GS | 1 |
| Zhang, XD | 1 |
| Lu, AP | 1 |
| Xia, HH | 1 |
| Lam, S | 1 |
| Tsai, YC | 1 |
| Wu, CT | 1 |
| Chang, WL | 1 |
| Graham, DY | 1 |
| Lehmann, FS | 1 |
| Gyr, N | 1 |
| Lamarque, D | 1 |
| Lai, KC | 1 |
| Chu, KM | 1 |
| Hui, WM | 1 |
| Hu, WH | 1 |
| Wong, WM | 1 |
| Chan, AO | 1 |
| Wong, J | 1 |
| Lam, SK | 1 |
| Liou, MF | 1 |
| Hiratsuka, T | 1 |
| Tatsuguchi, A | 1 |
| Ueki, N | 1 |
| Shinji, Y | 1 |
| Wada, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study on the Probiotics Regulating miRNA in H. Pylori-induced Wnt/β-catenin Gastric Carcinogenesis.[NCT05544396] | 100 participants (Anticipated) | Interventional | 2023-11-08 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for celecoxib and Infections, Helicobacter
| Article | Year |
|---|---|
[The future of peptic ulcer disease without Helicobacter].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin | 2003 |
7 trials available for celecoxib and Infections, Helicobacter
| Article | Year |
|---|---|
Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Celecoxib; China; Clarithromycin; Cyclooxygenase 2; Cyclo | 2015 |
Alterations of Cyclooxygenase-2 Methylation Levels Before and After Intervention Trial to Prevent Gastric Cancer in a Chinese Population.
Topics: Adult; Anti-Bacterial Agents; Asian People; Celecoxib; Chromatography, High Pressure Liquid; Cycloox | 2016 |
Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions.
Topics: Adult; Aged; Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2009 |
Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradication.
Topics: Aged; Atrophy; beta Catenin; Biomarkers; Blood Urea Nitrogen; Celecoxib; Creatinine; Cyclooxygenase | 2010 |
Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Celecoxib; Clarithromycin; Cyclooxygenase 2 Inhibitors; D | 2012 |
Long-term celecoxib can prevent the progression of persistent gastric intestinal metaplasia After H. pylori eradication.
Topics: Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Gastritis, Atrophic; Helicobacter Infections; | 2013 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2005 |
11 other studies available for celecoxib and Infections, Helicobacter
| Article | Year |
|---|---|
Celecoxib inhibits Helicobacter pylori-induced invasion of gastric cancer cells through an adenine nucleotide translocator-dependent mechanism.
Topics: Anoikis; Celecoxib; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2 Inhibitors; | 2013 |
New pharmaceutical treatment of gastric MALT lymphoma: anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib.
Topics: Angiogenesis Inhibitors; Animals; Antibodies; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models | 2014 |
Anti-LeY antibody enhances therapeutic efficacy of celecoxib against gastric cancer by downregulation of MAPKs/COX-2 signaling pathway: correlation with clinical study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cycl | 2015 |
Celecoxib inhibits apurinic/apyrimidinic endonuclease-1 expression and prevents gastric cancer in Helicobacter pylori-infected mongolian gerbils.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Disease Progression; DNA-(Apurinic or Apyrimidinic Si | 2008 |
Celecoxib inhibits CD133-positive cell migration via reduction of CCR2 in Helicobacter pylori-infected Mongolian gerbils.
Topics: AC133 Antigen; Adenocarcinoma; Animals; Antigens, CD; Blotting, Western; Celecoxib; Cell Count; Cell | 2010 |
Prostaglandin E₂ signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors.
Topics: Animals; Antibodies, Neutralizing; Benzamides; Celecoxib; Cell Line; Cell Transformation, Neoplastic | 2011 |
Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Barrett Esophagus; CDX2 Transcription Factor; Celeco | 2011 |
NSAIDs, Helicobacter pylori, and Pandora's Box.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; | 2002 |
[Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2004 |
Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Dyspepsia; Female; Gastric Mucosa; Helicobacter Infections; He | 2007 |
Celecoxib inhibits Cdx2 expression and prevents gastric cancer in Helicobacter pylori-infected Mongolian gerbils.
Topics: Animals; Biomarkers, Tumor; Biopsy, Needle; CDX2 Transcription Factor; Celecoxib; Disease Models, An | 2006 |